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Abstract
Background: To prove the feasibility of integrating CT urography (CTU) into 68Ga-PSMA-11 PET/CT and to analyze
the impact of CTU on assigning focal tracer accumulation in the ureteric space to either ureteric excretion or
metastatic disease concerning topographic attribution and diagnostic confidence.
Methods: Ten prostate cancer patients who underwent 68Ga-PSMA-11 PET/CT including CTU because of
biochemical relapse or known metastatic disease were retrospectively analyzed. CTU consisted of an excretory
phase 10 min after injection of 80 mL iodinated contrast material. Ureter opacification at CTU was evaluated using
the following score: 0, 0% opacification; 1, < 50%; 2, 50–99%; 3, 100%. Topographic attribution and confidence of
topographic attribution of focal tracer accumulation in the ureteric space were separately assessed for 68Ga-PSMA-
11 PET/CT without and with CTU. Diagnostic confidence was evaluated using the following score: 0, < 25%
confidence; 1, 26–50%; 2, 51–75%; 3, 76–100%.
Results: At CTU, mean ureter opacification score was 2.6 ± 0.7. At 68Ga-PSMA-11 PET/CT without CTU, mean
confidence of topographic attribution of focal tracer accumulation was 2.5 ± 0.7 in total and 2.6 ± 0.7 for metastatic
disease. At 68Ga-PSMA-11 PET/CT with CTU, mean confidence of topographic attribution of focal areas of tracer
accumulation was significantly higher with 2.9 ± 0.2 in total and 2.7 ± 0.9 for metastatic disease (p < 0.001). In 4 of
34 findings (12%) attribution to either ureteric excretion or metastatic disease was discrepant between 68Ga-PSMA-
11 PET/CT without and with CTU (n.s).
Conclusions: Integration of CTU into 68Ga-PSMA-11 PET/CT is feasible and increases diagnostic confidence of
assigning focal areas of tracer accumulation in the ureteric space to either metastatic disease or ureteric excretion.
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Background
Prostate Cancer is the most common malignancy in
men and the third most frequent cause of cancer-
associated death [1, 2]. With the introduction of
prostate-specific antigen (PSA) screening, many patients
are diagnosed with localized disease, but still a subset of
patients develops high-risk or metastatic disease. After
radical treatment of localized disease, biochemical
relapse according to PSA elevation occurs in approxi-
mately 30% of prostate cancer patients [3].
Accurate diagnosis of prostate cancer relapse, identifi-
cation of involved anatomical sites, and assessment of
tumor load are crucial for treatment stratification and
metastases-directed therapies such as salvage lymph
node dissection. Early detection of prostate cancer
relapse is, however, a major challenge for conventional
imaging methods including computed tomography (CT)
and magnetic resonance imaging (MRI) [4]. Functional im-
aging techniques targeting the prostate-specific membrane
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antigen (PSMA) using positron emission tomography
(PET) have shown great potential for detection of prostate
cancer and its metastases [5]. A key step in PET imaging
with PSMA ligands was the development of 68Ga-labelled
PSMA (68Ga-PSMA-11) [6]. 68Ga-PSMA-11 binds to the
extracellular part of the PSMA receptor and is then inter-
nalized into the prostate cancer cell.
68Ga-PSMA-11 is eliminated via the renal pathway, so
that detection of disease with PET/CT using 68Ga-
PSMA-11 may be limited by topographic proximity of
tumor sites with the urinary tract or by superimposition
of tumor sites and ureteric tracer accumulation [7].
Furthermore, the low-dose CT scan of a conventional
68Ga-PSMA-11 PET/CT may be limited in regards of
anatomical landmarking and, thus, may have limited
diagnostic confidence to correctly classify a focal tracer
accumulation as tumor uptake or ureteric tracer excre-
tion. Hence, improving visualization of the upper urinary
tract using CT urography (CTU) as the first choice im-
aging technique to depict the urinary tract may have
added value for 68Ga-PSMA-11 PET/CT if conducted
after the regular PET/CT scan.
The aim of this retrospective study was to evaluate the
integration of CTU into 68Ga-PSMA-11 PET/CT. We
hypothesized that availability of a CTU scan improves
diagnostic confidence of attributing focal areas of tracer
accumulation in the ureteric space to either ureteric
tracer excretion or tumor uptake at 68Ga-PSMA-11
PET/CT.
Methods
Study design and study population
This retrospective single-center exploratory study was
approved by the local institutional review board (S-321/
2012) and conducted in agreement with the Declaration
of Helsinki and its later amendments. In 10 consecutive
patients, in which 68Ga-PSMA-11 PET/CT was per-
formed for standard clinical indications, 68Ga-PSMA-11
PET/CT was supplemented by CTU at the discretion of
the attending nuclear medicine physician. Clinical data
was extracted from the electronical medical records.
Imaging
All patients underwent imaging on a Biograph mCT Flow
scanner (Siemens, Erlangen, Germany). FlowMotion was
used to acquire PET in 3D mode (matrix 200 × 200).
Correction for randoms, scatter and decay was performed
for the emission data. Images were reconstructed with an
ordered subset expectation maximization (OSEM) algo-
rithm with two iterations/21 subsets and Gauss-filtered to
a transaxial resolution of 5 mm at full-width at half-
maximum (FWHM). Attenuation was corrected using
unenhanced low-dose CT reconstructed to a slice thick-
ness of 5 mm with an increment of 3–4 mm.
CTU was performed during the same 68Ga-PSMA-11
PET/CT session on the same scanner. All patients re-
ceived a bolus of 80 mL intravenous iodine-based con-
trast agent (iopromide, 300 mg per mL, Ultravist, Bayer,
Leverkusen, Germany) via injection. The excretory phase
of CTU was finally performed 600 s after injection (slice
thickness, 2.0 mm; reconstruction increment, 1.6 mm;
tube voltage, 120 kVp; reference tube current time prod-
uct, 190 mAs). Additional means to intensify ureteric
opacification at CTU, such as furosemide injection, were
not undertaken.
Image analysis
Two independent analyses of image data sets were
performed: First, contrast opacification of the lumen
of the ureters at CTU was assessed to investigate the
quality of CTU. Second, the confidence of attributing
a PET-positive finding in the ureteric space to
metastatic disease or ureteric tracer excretion was
determined.
In order to assess the contrast enhancement of the
ureters two blinded board-certified readers with more
than 10 years of experience in abdominal radiology
each (FLG, TFW) reviewed CTU images independ-
ently on an imaging workstation (Centricity, GE
Healthcare, Chalfont St. Giles, Great Britain). The
ureters were divided into a proximal segment above
the iliac vessels and a distal segment below the iliac
vessels. The readers were advised to assign an opacifi-
cation score to each section according to the CTU
analyses published by other groups before [8]. The
opacification scores were the following: 0, 0% opacifi-
cation; 1, < 50% opacification; 2, 50–99% opacifica-
tion; 3, 100% opacification.
In order to assess the confidence of attributing a
PET-positive finding in the ureteric space to tumor up-
take or ureteric tracer excretion a two-step analysis was
performed by one reader (TFW). First, fused unen-
hanced 68Ga-PSMA-11 PET/CT images were reviewed
without consideration of the CTU scan (confidence
read 1). Focal areas of tracer accumulation in the ur-
eteric space were identified and attributed either to
tumor uptake or ureteric tracer excretion. Diagnostic
confidence of assignment was recorded using the
following confidence score: 0, < 25% confidence; 1, 26–
50% confidence; 2, 51–75% confidence; 3, 76–100%
confidence. Second, four weeks after confidence read 1
the examinations were read again including the CTU
scan (confidence read 2). PET-positive findings identi-
fied at confidence read 1 were anatomically correlated
to the CTU scan. Again, diagnostic confidence of
attributing focal areas of tracer accumulation in the ur-
eteric space to either tumor uptake or ureteric tracer
excretion was scored for each finding.
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Statistics
Interreader agreement of the assessment of ureter opaci-
fication was calculated by using the intraclass coefficient
(ICC) employing a two-way consistency model indicat-
ing that the absolute differences were neglected. The
average-measures ICC is given with 95% confidence
interval. 0.00 to 0.20 indicates slight agreement, 0.21 to
0.40 fair agreement, 0.41 to 0.60 moderate agreement,
0.61 to 0.80 substantial agreement, and 0.81 to 1.00 al-
most perfect or perfect agreement. Differences in ana-
tomical attribution of PET-positive findings and
differences in diagnostic confidence of anatomical attri-
bution were analyzed using Wilcoxon signed-rank tests
for paired samples.
Results
Patients
The study group consisted of 10 men with a median age
of 70 years (range, 63–81). Indication for 68Ga-PSMA-11
PET/CT was biochemical relapse after radical prostatec-
tomy in 8 patients, staging prior to treatment in 1 pa-
tient, and re-staging during hormonal therapy in 1
patient, respectively. For 5 patients, long-term onco-
logical follow-up data was available. Of these patients, 4
had confirmed advanced/metastatic disease diagnosed at
68Ga-PSMA-11 PET/CT, and tumor-specific therapy was
initiated. 1 patient had no morphological sign of disease
recurrence despite PSA progression but developed re-
current tumor later on during the course of disease. For
the other 5 patients, PSMA CT revealed recurrent ad-
vanced diseases in 3 patients, and in 2 cases no tumor
activity was detected. Clinical characteristics are summa-
rized in Table 1.
Opacification score
In total, 40 ureter segments (10 patients, 4 segments per
patient) have been evaluated. Ureter opacification was
scored by reader 1 with a mean score of 2.5 ± 0.6 and by
reader 2 with a mean score of 2.7 ± 0.7. The total opaci-
fication score averaged over both readers was 2.6 ± 0.7.
Both readers demonstrated near perfect agreement for
all ratings taken together (ICC, 0.86 (0.79–0.91)). Table 2
shows the mean score for each segment by each reader
and the interreader agreement per segment.
Reader 1 rated opacification of 34 of 40 segments
(85%) with a score of at least 2. Reader 2 rated opacifica-
tion of 33 of 40 segments (82.5%) with a score of at least
2. The quantitative distribution of ureteric opacification
scores is given in Table 3.
Diagnostic confidence
In confidence read 1, considering fused images of the
unenhanced PET/CT alone, 34 focal areas of tracer accu-
mulation in the ureteric space were identified. Of these,
14 were attributed to tumor uptake. Mean confidence of
attribution in read 1 was 2.5 ± 0.7 in total and 2.6 ± 0.7
for tumor uptake.
In confidence read 2, considering fused images of the
unenhanced PET/CT and CTU together, attribution of
focal areas of tracer accumulation to tumor uptake or ur-
eteric excretion was discrepant from confidence read 1 in
4 of 34 findings (12%) or 2 of 10 patients (20%), respect-
ively. Three of these discrepancies occurred in one patient
and consisted of attribution of tracer accumulation to ur-
eteric excretion rather than to tumor uptake (Fig. 1). In
this patient, other focal areas of tracer accumulation attrib-
uted to tumor uptake in both reads were present as well.
The remaining discrepancy consisted of attribution of
tracer accumulation to tumor uptake rather than to ur-
eteric excretion in a different patient (Fig. 2). In this pa-
tient, other focal areas of tracer accumulation attributed to
tumor uptake were not present. The confidence score dif-
fered from read 1 in 15 findings (44%). In 14 of these 15
findings the confidence score in read 2 was at least 1 grade
higher than in read 1. Mean confidence of attribution in
read 2 was 2.9 ± 0.2 in total and 2.7 ± 0.9 for tumor uptake.
Table 1 Clinical characteristics of study patients
Patient number Age Extent of disease at 68Ga-PSMA-11 PET/CT Initiation of tumor specific therapy
1 72 Advanced/metastatic Yes
2 63 Advanced/metastatic Unknown
3 81 Advanced/metastatic Unknown
4 67 Advanced/metastatic Unknown
5 63 No morphological recurrence Not available
6 71 Advanced/metastatic Yes
7 71 Local tumor Yes
8 64 Advanced/metastatic Yes
9 70 No morphological recurrence Not available
10 53 No morphological recurrence Not available
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Anatomic attribution of focal areas of tracer accumu-
lation to either tumor uptake or ureteric excretion did
not differ significantly between confidence read 1 and 2
in total (p = 0.375). The confidence of attribution was
significantly higher for the combined read of PET/CT
and CTU than for PET/CT alone (p < 0.001) (Fig. 3).
CTU radiation exposure
The mean CT volume dose index (CTDIvol) and dose
length product (DLP) of CTU were 15 ± 6 mGy and 694
± 334 mGycm.
Discussion
The present analysis demonstrates that integration of
CTU into 68Ga-PSMA-11 PET/CT imaging of prostate
cancer patients is feasible and increases diagnostic confi-
dence of attribution of focal areas of tracer accumulation
in the ureteric space to either tumor uptake or ureteric
excretion. In a considerable amount of focal areas of
tracer accumulation integration of CTU changed the as-
sessment of anatomic allocation (12%) and, thus, may
impact on cancer patient management in select cases.
Nowadays, 68Ga-PSMA-11 PET/CT plays an import-
ant role in management of prostate cancer patients [9].
Especially in the event of biochemical relapse, early de-
tection of recurrent disease is of major importance to
identify individuals that are eligible for curative treat-
ment options including salvage lymphadenectomy. In a
study of 319 patients with biochemical failure after cura-
tively intended therapy more than 80% of patients had at
least one positive lesion at 68Ga-PSMA-11 PET/CT [10].
The probability of a positive 68Ga-PSMA-11 PET/CT in-
creases with the blood level of PSA: For PSA levels be-
tween 0.5 and 1.0 ng/mL it is almost 60% and rises
rapidly with increasing PSA levels [10, 11]. In a recent
meta-analysis, overall sensitivity and specificity were
about 86% for per-patient analysis and 80% and 97% for
per-lesion analysis, respectively [11].
A ligand-specific challenge is evaluation of tumor foci
in close proximity to ureter and bladder because of urin-
ary excretion of 68Ga-PSMA-11 [7, 12]. A focal tracer
accumulation in the retroperitoneum and pelvis can be
misinterpreted because the low-dose scan typically
included in standard PET/CT imaging may not offer
sufficient anatomical detail to correctly identify the
underlying cause of accumulation, especially for the in-
experienced reader. Thus, urinary excretion of 68Ga-
PSMA-11 may influence data on false positive and false
negative lymph node assessment at 68Ga-PSMA-11 PET/
CT [13–15]. As the problem of identification of local re-
currences in the prostate bed, that may be obscured by
tracer activity within the bladder, was considered not to
be addressed by CTU integration, the ability of detecting
local recurrences beneath the ureter orifices was not
subject of this study.
Although uncertainty of anatomical attribution of focal
areas of tracer accumulation may be present only in a
minority of cases, the impact of over- or understaging
disease on patient management may be tremendous and
may justify integration of an additional CTU scan at
least in select cases with equivocal findings at standard
68Ga-PSMA-11 PET/CT. Due to the small size of our
study cohort and lack of long-term clinical data in half
of our patients, impact of CTU integration on specific
oncological treatment decisions and patient outcome
cannot be derived from the results.
The standard CTU protocol consists of unenhanced,
nephrographic phase, and excretory phase imaging. Com-
mon general indications for CTU include hematuria, sta-
ging and follow-up of urothelial cancer, urinary tract
obstruction, and anomalies of urinary tract anatomy [16].
It does not only allow detailed assessment of the urinary
tract but also facilitates evaluation of adjacent abdominal
and pelvic structures. The urography protocol used in this
study was a single-bolus technique with administration of
80 ml of contrast material and excretory phase imaging
10 min after injection. Although the frequently recom-
mended amount of contrast material for CTU is 100 to
150 ml, opacification of the urinary tract was sufficient in
our study even in distal ureter segments [17]. As anatomic
delineation of the ureter and not evaluation of the upper
urinary tract for urothelial masses was the intention for
CTU, the reduction of the amount of contrast material
was justified. For the same reason we did not use oral
hydration, intravenous saline infusion, or furosemide in-
jection to intensify ureter distention - techniques that have
been suggested to improve assessment of the upper urin-
ary tract [18–20].
Table 2 Ureter opacification scoring and interreader agreement
Segment ICC (95% CI) Reader 1 Reader 2
Left proximal ureter 0.96 (0.85–0.99) 2.5 ± 0.9 2.4 ± 0.8
Right proximal ureter 1.00 2.7 ± 0.7 2.7 ± 0.7
Left distal ureter 0.87 (0.49–0.97) 2.0 ± 0.7 2.1 ± 1.0
Right distal ureter 0.82 (0.29–0.96) 2.2 ± 0.4 2.3 ± 0.8
All ratings combined 0.86 (0.79–0.91) 2.5 ± 0.6 2.7 ± 0.7
Table 3 Distribution of ureteric opacification scores
Opacification score Reader 1 (%
of segments)
Reader 2 (%
of segments)
3 20 (50) 23 (58)
2 14 (35) 10 (25)
1 6 (15) 6 (15)
0 0 (0) 1 (3)
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Because a standard dose contrast enhanced CT scan
during nephrographic or portal venous phase was not per-
formed in our study, it remains unclear if such an acquisi-
tion would provide similar results to CTU regarding
anatomic attribution of focal tracer accumulations. A
nephrographic or portal venous phase was not acquired
because sole visceral metastases are rare in prostate cancer
patients, the excretory phase is considered to be superior
for exact urinary tract depiction, and it would have added
even more additional radiation exposure to the diagnostic
procedure. Of note, using a split bolus technique for CTU,
simultaneous acquisition of a nephrographic and excre-
tory phase has been introduced as an alternative one-stop-
shop CTU technique with reduced radiation dose [8, 21].
CTU was done in our study with standard abdominal
scanning parameters with 120 kVp and image reconstruc-
tion using filtered back projection. Studies have shown
that iterative image reconstruction or reduction of tube
voltage to 100 kVp may allow significant dose reduction
without decline of CTU image quality [22, 23]. Iterative
reconstruction is already available on modern PET/CT
scanners and may be preferred over filtered back projec-
tion for diagnostic contrast enhanced dose reduced body
scans. An alternative to CTU could be to increase ureteric
clearance of 68Ga-PSMA-11 by injection of furosemide
prior to the delayed PET scan and adding another unen-
hanced low-dose scan of the abdomen and pelvis for ana-
tomical correlation. Derlin et al. have shown that forced
Fig. 1 Discrepancies for 68Ga-PSMA-11 PET/CT without and with CTU in anatomical assignment of tracer accumulation in a patient with
multifocal retroperitoneal nodal relapse. a shows focal tracer accumulation in the right iliac retroperitoneum that was assigned to tumor uptake
in 68Ga-PSMA-11 PET/CT alone (arrow in a, confidence score 1) and to right ureteric excretion in 68Ga-PSMA-11 PET/CT with CTU (arrow heads in
b refer to both ureters, confidence score 3). c again shows focal tracer accumulation in the right iliac retroperitoneum that was assigned to
tumor uptake in 68Ga-PSMA-11 PET/CT alone (arrow in c, confidence score 1) and to right ureteric excretion in 68Ga-PSMA-11 PET/CT with CTU
(arrow heads in b refer to both ureters, confidence score 3). There is another focal tracer accumulation that was assigned to metastatic disease in
68Ga-PSMA-11 PET/CT without and with CTU (curved arrow in c and d, both confidence score 3)
Fig. 2 Discrepancies for 68Ga-PSMA-11 PET/CT without and with CTU in anatomical assignment of tracer accumulation in a patient with unifocal
retroperitoneal nodal relapse according to 68Ga-PSMA-11 PET/CT with CTU. a shows a focal tracer accumulation in the left retroperitoneum at the the
level of the ureteric crossing of the iliac vessels with anatomical assignment to the left ureter with confidence score 1. Using 68Ga-PSMA-11 PET/CT
with CTU, the focus was assigned to a small periureteric soft tissue mass (circle in b) between the left ureter (arrow head in b) and the left iliac vessels
with confidence score 3
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diuresis with furosemide injection may reduce linear and
focal tracer accumulation in standard 68Ga-PSMA-11
PET/CT and, thus, may improve image quality without
the need of intravenous contrast administration and CTU
scanning [24]. However, correct timing of furosemide in-
jection seems to be crucial in this approach as too early
furosemide injection may even deteriorate image quality.
Today, several PSMA ligands aside from 68Ga-PSMA-
11 are available: 68Ga-PSMA-I + T, 68Ga-PSMA-617 as
well as 18F–DCFBC, 18F–DCPyL, and, most recently,
18F–PSMA-1007. All of these PSMA-ligands have simi-
lar characteristics in regards of tumor uptake and tracer
clearance except for 18F–PSMA-1007 [12, 25–28]. This
ligand is cleared primarily via the hepatobiliary route
and not via the urinary tract and may improve diagnos-
tic confidence particular in these suspicious areas [12].
Limitations
This retrospective study is limited by small sample size
and, thus, can only be considered hypothesis-generating.
It cannot be derived from our data how often integration
of CTU into 68Ga-PSMA-11 PET/CT may actually change
oncological patient management and influence long-term
clinical outcome. Larger and prospectively generated co-
horts are to be studied to fully assess the clinical benefit of
our method. As histological correlation of imaging find-
ings was not undertaken, a gold standard to estimate the
diagnostic accuracy of 68Ga-PSMA-11 PET/CT with and
without CTU including rates of false positive and false
negative findings is not available. Data on interrater reli-
ability of the improvement of diagnostic confidence are
not available.
Conclusions
Integration of CTU into 68Ga-PSMA-11 PET/CT may
help the imaging specialist in anatomical attribution
of questionable findings and enhance confidence in
interpretation of 68Ga-PSMA-11 PET/CT scans in
select cases.
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